Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q2 2026 · 10-Q
Revenue$8.80M$8.80M−18.8% vs Q2 2025 Net Income-$4.28M-$4.28MN/M vs Q2 2025 EPS Diluted-$0.29-$0.29N/M vs Q2 2025 Operating Income-$3,160,461N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$130,457−84.0% Margins · derivedOperating margin-35.9%−7.1 pt vs Q2 2025
Net margin-48.6%−41.8 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 7, 2026 · 38 d after period end